Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 6
2010 2
2011 2
2012 1
2014 2
2015 2
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia--Comparison among Different Treatment Strategies.
Matloub Y, Stork L, Asselin B, Hunger SP, Borowitz M, Jones T, Bostrom B, Gastier-Foster JM, Heerema NA, Carroll A, Winick N, Carroll WL, Camitta B, Devidas M, Gaynon PS. Matloub Y, et al. Pediatr Blood Cancer. 2016 Feb;63(2):255-61. doi: 10.1002/pbc.25793. Epub 2015 Oct 20. Pediatr Blood Cancer. 2016. PMID: 26485054 Free PMC article.
Overall 7-year survivals were 86.1 4.6%, 88.3 4.4%, 89.1 3.6%, respectively (P = 0.84). CONCLUSIONS: Comparable high rates of EFS and long-term survival were achieved with all three regimens, with the CCG regimens utilizing a less intensive chemotherapy backbone without pr …
Overall 7-year survivals were 86.1 4.6%, 88.3 4.4%, 89.1 3.6%, respectively (P = 0.84). CONCLUSIONS: Comparable high rates of EFS and long- …
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.
Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, Vora A, Baruchel A, Silverman LB, Schmiegelow K, Escherich G, Horibe K, Benoit YC, Izraeli S, Yeoh AE, Liang DC, Downing JR, Evans WE, Relling MV, Mullighan CG. Pui CH, et al. J Clin Oncol. 2015 Sep 20;33(27):2938-48. doi: 10.1200/JCO.2014.59.1636. Epub 2015 Aug 24. J Clin Oncol. 2015. PMID: 26304874 Free PMC article. Review.
The resulting article was reviewed and revised by the committee chairs of the major ALL study groups. RESULTS: With long-term survival rates for ALL approaching 90% and the advent of high-resolution genome-wide analyses, several international study groups or consortia were …
The resulting article was reviewed and revised by the committee chairs of the major ALL study groups. RESULTS: With long-term surviva …
Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031.
Friedman DL, Chen L, Wolden S, Buxton A, McCarten K, FitzGerald TJ, Kessel S, De Alarcon PA, Chen AR, Kobrinsky N, Ehrlich P, Hutchison RE, Constine LS, Schwartz CL. Friedman DL, et al. J Clin Oncol. 2014 Nov 10;32(32):3651-8. doi: 10.1200/JCO.2013.52.5410. Epub 2014 Oct 13. J Clin Oncol. 2014. PMID: 25311218 Free PMC article. Clinical Trial.
PURPOSE: The Children's Oncology Group study AHOD0031, a randomized phase III study, was designed to evaluate the role of early chemotherapy response in tailoring subsequent therapy in pediatric intermediate-risk Hodgkin lymphoma. To avoid treatment-associated risks that compromi …
PURPOSE: The Children's Oncology Group study AHOD0031, a randomized phase III study, was designed to evaluate the role of early chemotherapy …
Family life events in the first year of acute lymphoblastic leukemia therapy: a children's oncology group report.
Lau S, Lu X, Balsamo L, Devidas M, Winick N, Hunger SP, Carroll W, Stork L, Maloney K, Kadan-Lottick N. Lau S, et al. Pediatr Blood Cancer. 2014 Dec;61(12):2277-84. doi: 10.1002/pbc.25195. Epub 2014 Aug 30. Pediatr Blood Cancer. 2014. PMID: 25175168 Free PMC article.
No unifying factor was associated with the different family events. Ongoing follow-up is planned to measure long-term outcomes....
No unifying factor was associated with the different family events. Ongoing follow-up is planned to measure long-term outcomes....
Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.
Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz SE, Krailo M, Devidas M, Barkauskas DA, Siegal GP, Ferguson WS, Letson GD, Marcus K, Goorin A, Beardsley P, Marina N. Ebb D, et al. J Clin Oncol. 2012 Jul 10;30(20):2545-51. doi: 10.1200/JCO.2011.37.4546. Epub 2012 Jun 4. J Clin Oncol. 2012. PMID: 22665540 Free PMC article. Clinical Trial.
For patients without HER2 overexpression, treated with chemotherapy alone, the 30-month event-free and overall survival rates were 32% and 50%, respectively. There was no clinically significant short-term cardiotoxicity in patients treated with trastuzumab and doxorubicin. …
For patients without HER2 overexpression, treated with chemotherapy alone, the 30-month event-free and overall survival rates were 32% and 5 …
Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children's Oncology Group.
Malogolowkin MH, Katzenstein HM, Meyers RL, Krailo MD, Rowland JM, Haas J, Finegold MJ. Malogolowkin MH, et al. J Clin Oncol. 2011 Aug 20;29(24):3301-6. doi: 10.1200/JCO.2010.29.3837. Epub 2011 Jul 18. J Clin Oncol. 2011. PMID: 21768450 Free PMC article. Clinical Trial.
CONCLUSION: Children with completely resected PFH hepatoblastoma can achieve long-term survival without additional chemotherapy. When feasible, surgical resection of hepatoblastoma at diagnosis, without chemotherapy, can identify children for whom no additional therapy is …
CONCLUSION: Children with completely resected PFH hepatoblastoma can achieve long-term survival without additional chemotherapy. When …
Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group.
Walterhouse DO, Meza JL, Breneman JC, Donaldson SS, Hayes-Jordan A, Pappo AS, Arndt C, Raney RB, Meyer WH, Hawkins DS. Walterhouse DO, et al. Pediatr Blood Cancer. 2011 Jul 15;57(1):76-83. doi: 10.1002/pbc.22928. Epub 2011 Feb 4. Pediatr Blood Cancer. 2011. PMID: 21298768 Free PMC article. Clinical Trial.
CONCLUSIONS: To prevent local recurrence, we recommend a local control approach for patients with non-resected RMS of the vagina that is similar to that used for other primary sites and includes RT. We recognize that potential long-term effects of RT are sometimes unaccept …
CONCLUSIONS: To prevent local recurrence, we recommend a local control approach for patients with non-resected RMS of the vagina that is sim …
Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia.
Kadan-Lottick NS, Brouwers P, Breiger D, Kaleita T, Dziura J, Northrup V, Chen L, Nicoletti M, Bostrom B, Stork L, Neglia JP. Kadan-Lottick NS, et al. J Clin Oncol. 2009 Dec 10;27(35):5986-92. doi: 10.1200/JCO.2009.23.5408. Epub 2009 Nov 2. J Clin Oncol. 2009. PMID: 19884541 Free PMC article. Clinical Trial.
PURPOSE: For the majority of children with acute lymphoblastic leukemia (ALL), CNS prophylaxis consists of either intrathecal (IT) methotrexate or triple IT therapy (ie, methotrexate with both cytarabine and hydrocortisone). The long-term neurotoxicities of these two IT st …
PURPOSE: For the majority of children with acute lymphoblastic leukemia (ALL), CNS prophylaxis consists of either intrathecal (IT) methotrex …
14 results